Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
易普利姆玛
前列腺癌
医学
免疫系统
肿瘤科
内科学
前列腺
癌症
免疫学
免疫疗法
作者
Sumit K. Subudhi,Luis M. Vence,Hao Zhao,Jorge Blando,Shalini S. Yadav,Qing Xiong,Alexandre Reuben,Ana Aparicio,Paul G. Corn,Brian F. Chapin,Louis L. Pisters,Patricia Troncoso,Rebecca S.S. Tidwell,Peter F. Thall,Chang‐Jiun Wu,Jianhua Zhang,Christopher L. Logothetis,P. Andrew Futreal,James P. Allison,Padmanee Sharma
出处
期刊:Science Translational Medicine [American Association for the Advancement of Science (AAAS)] 日期:2020-04-01卷期号:12 (537)被引量:124
Low–tumor mutational burden prostate tumors express neoantigens that elicit T cell responses associated with favorable clinical outcomes to ipilimumab.